Summary
Cencora, Inc. (COR) has filed an 8-K report detailing amendments to its securitization facility. The most significant change is the extension of the facility's termination date from October 21, 2025, to October 21, 2026. This extension provides Cencora with continued access to a crucial liquidity and funding source for its ongoing business operations. The facility, which has a base limit of $1.45 billion and an option to increase by $250 million for seasonal needs, relies on accounts receivables from pharmaceutical sales and related services provided by its subsidiaries ABDC and ASD Specialty Healthcare, LLC. Additionally, the amendments introduce U.S. Bank National Association and Truist Bank as new committed purchasers while removing Mizuho Bank, Ltd. The report also notes technical changes to reflect the company's new name, Cencora, Inc. These updates to the securitization facility are important for investors as they ensure continued financial flexibility and operational support for Cencora's business.
Key Highlights
- 1Cencora, Inc. extended its securitization facility's termination date by one year, from October 21, 2025, to October 21, 2026.
- 2The facility provides significant liquidity and funding for ongoing business needs, with a base limit of $1.45 billion and a potential increase of $250 million for seasonal demands.
- 3New financial institutions, U.S. Bank National Association and Truist Bank, have been added as committed purchasers to the facility.
- 4Mizuho Bank, Ltd. has been removed as a committed purchaser from the facility.
- 5Amendments were made to reflect the company's updated name to Cencora, Inc.
- 6The facility is backed by accounts receivables generated from the sale of pharmaceuticals and related services by subsidiaries ABDC and ASD Specialty Healthcare, LLC.